Applications of body surface mapping in cardiac resynchronisation therapy and ventricular tachycardia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN35782567

Enrollment

Registered

2007-07-30

Start date

2005-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left ventricular dysfunction Circulatory System Left ventricular dysfunction

Interventions

1. CRT study This is a pilot study during which 50 consecutive patients undergoing CRT implantation will be identified and worked up appropriately (there is no control group in this study and all par

Eligibility

Inclusion criteria

Inclusion criteria: Cardiac Resynchronization Therapy (CRT) study: 1. Poor LV function with ejection fraction on echocardiogram (ECHO) 55 mm) 4. Any QRS duration (representing the duration of ventricular depolarisation) LV dysfunction can be of any aetiology. All patients must be able and willing to give writted informed consent. ECGI validation study: Patients must require EPS/ablation of tachyarrhythmias requiring LV access e.g. VT ablation/EPS, Brugada EPS, left sided pathways. All must be willing and able to give written informed consent. VT study: All patients must require EPS for induction of LV tachyarrhythmias or ablation of VT. Again all must give written informed consent.

Exclusion criteria

Exclusion criteria: CRT study: 1. Ejection fraction on ECHO >35% 2. Unable or unwilling to come back for 6 month follow-up 3. Unable or unwilling to give written informed consent ECGI validation and VT studies: 1. Procedures not requiring access to the LV 2. Bleeding conditions 3. Clotting disorders 4. Unwilling to give written informed consent 5. Age <18 years

Design outcomes

Primary

Measure	Time frame
CRT study: Response to CRT (assessed clinically using echo, 6 minute walk distance, cardiopulmonary stress testing, and functionally using quality of life questionnaire and NYHA symptom class). This can be assessed in conjunction with pacing site localisation using ECGI in relation to regions of slow conduction/scar tissue. ECGI validation and VT studies: These are qualitative studies whereby ECGI data and data acquired invasively are compared directly. Therefore there is no discrete end-point.	—

Measure

Time frame

CRT study: Response to CRT (assessed clinically using echo, 6 minute walk distance, cardiopulmonary stress testing, and functionally using quality of life questionnaire and NYHA symptom class). This can be assessed in conjunction with pacing site localisation using ECGI in relation to regions of slow conduction/scar tissue. ECGI validation and VT studies: These are qualitative studies whereby ECGI data and data acquired invasively are compared directly. Therefore there is no discrete end-point.

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026